|
Online Database of Chemicals from Around the World | 产品搜索 | 产品提交 | 产品推广 |
网站主页 >> 化工产品目录 >> 丹诺普韦>> 市场分析报告 |
丹诺普韦市场分析报告 |
|
CAS 916826-48-7 Danoprevir sodium salt Chemical Report & Database ... data on the net consumption of Danoprevir sodium salt in each of the ... Report & Database definitions: Name: Danoprevir sodium salt: Danoprevir-sodium-salt; 4-Fluoro-1,3- ... : Chemical or Reaction Intermediate The Danoprevir sodium salt Report & Database gives ... Pharmasset, Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis ... of RG7128 in combination with ritonavir-boosted danoprevir. Roche is also planning to conduct a Phase ... Hepatitis C Market & Forecast, HCV Drugs Clinical Trials, Hepatitis C Pipeline Drugs Sales & Forecast - Worldwide ... II) (Chapter No. 6) 1. Mericitabine (RG-7128) (Company: Roche) 2. Danoprevir/r (Ritonavir) (RG7227) (Company: Roche) 3. GS-9256 ... -072/333 8. Alisporivir 9. Mericitabine (RG-7128) 10. Danoprevir (RG7227) 11. GS-9256 12. Setrobuvir (ANA-598 ... Hepatitis C: Drug Development Pipeline Study, H2 2018 With an estimated market value of over $30 billion by 2020, the Hepatitis C industry is considered as the rapidly growing healthcare markets. Hepatitis C affects around 200 million people worldwide and is associated with highest treatment failure rates. ... KOL Insight: Hepatitis C: the Race for the First Interferon-free Regimen Analyzing the Hepatitis C Market Landscape After more than a decade of limited treatment options, the hepatitis C (HCV) market is on the cusp of a treatment revolution. In 2011, protease inhibitors-Incivek (telaprevir; Vertex) and Victrelis (boceprevir; ... Hepatitis C: Game changing regimens to revolutionise treatment landscape - KOL Insight Approval of Gilead’s once daily oral nucleotide inhibitor Sovaldi marks a significant step in the treatment of hepatitis C (HCV). With efficacy over 90% in GT1/2/3/4 patients, this safe, best in class therapy represents a paradigm shift compared to the ... 2020 COVID-19 Clinical Trials Guide- Companies, Drugs, Phases, Subjects, Current Status and Outlook to 2025 ... , CYP-001, CYT107, Daclatasvir, Dalteparin, Danoprevir, Dapagliflozin, DARUNAVIR, DAS181, Decitabine, Deferiprone ... COVID-19 Therapy and Vaccine Drug Pipeline and Clinical Trials Report- September 2020 Update ... , CYP-001, CYT107, Daclatasvir, Dalteparin, Danoprevir, Dapagliflozin, DARUNAVIR, DAS181, Decitabine, Deferiprone ... Hepatitis C (HCV) Market Forecast & Drugs Pipeline Analysis to 2016 ... 598), RG-7128, TMC - 435 and Danoprevir are going to be the next game ... |